Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Amendments to Investment Management Agreement

11th Jun 2009 07:00

RNS Number : 7053T
China Real Estate Opportunities PLC
11 June 2009
 



11 June 2009

CHINA REAL ESTATE OPPORTUNITIES PLC

Amendments to Investment Management Agreement

The Board of China Real Estate Opportunities plc announces that, following a review of the investment advisory agreement, dated 25 June 2007, between the Company and Treasury Holdings China Limited (the "Investment Manager"), the following amendments to the terms of that agreement have been agreed. These changes will eliminate from any future performance fee calculation (i) any increase in the value of RMB against Sterling; and (ii) any increase in net asset value per share arising from the Company repurchasing its shares. 

For the purposes of calculating any future entitlement to performance fees:

the European Public Real Estate Association net asset value at the end of each financial period will be restated in RMB. The payment of a performance fee remains subject to a high water mark which will initially be determined by reference to the Company's net assets as at 31 December 2008 expressed in RMB at the exchange rate prevailing on that date;

2. if the Company repurchases its own shares during any relevant period, the net asset value

per share at the end of that period will be adjusted so as to eliminate the impact of the

share repurchases on net asset value per share.

At the same time as agreeing the above the Board has taken the opportunity to tie the Investment Manager to the contract for a further two years so that, except in certain specified circumstances, the earliest date on which notice may be given will be in July 2012. 

These amendments are effective from 1 January 2009. The other terms of the investment advisory agreement remain unchanged.

- ENDS -

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Matrix Corporate CapitalPaul Fincham

Tel +44 (0) 20 3206 7000

Davy

Des Carville

Tel: +353 1 679 6363

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)20 7367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRSFWFISSUSEDM

Related Shares:

Creo Medical
FTSE 100 Latest
Value8,275.66
Change0.00